MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ckj/sfaf267

Медицинская библиотека · Clinical kidney journal · 2025

Drivers of hospital costs in ANCA-associated vasculitis patients with long-term follow-up-a real-world cost analysis.

van Leeuwen Jolijn R, Soltani Frouzan H, van den Hout Wilbert B, Rabelink Ton J, Teng Y K Onno

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a potentially life-threatening, systemic autoimmune disease with a high risk for relapse and treatment-related toxicity, making AAV a high-costs illness. This study aimed to identify clinical insights for clinicians on considering this costs burden.

METHODS

We conducted a detailed, retrospective, single-centre, activity-based cost-analysis and identified clinical variables associated with increased costs. We analysed real-world costs incurred by the hospital between January 2018 and December 2019, omitting the outpatient pharmacy expenditures. Our cohort included both incident and prevalent AAV patients with at least 6 months of follow-up since diagnosis, indicating survival beyond initial diagnosis.

RESULTS

For 180 AAV patients with a median follow-up of 1.8 years the average hospital costs incurred amounted to €9887 per patient year, with inpatient care being the primary cost driver (32%). Merely 15% of costs were attributable to patients experiencing relapse (N = 14/180, 8%). More importantly, 71% of costs were attributable to patients experiencing infections (N = 77/180, 43%). Likewise, 60% of costs were attributable to patients with multi-comorbidity (N = 65/180, 36%). Infections and multi-comorbidity were both strongly associated with corticosteroid (CS) use. Regression and sensitivity analyses suggest that a reduction of infections, comorbidities and maintenance treatment with CS will reduce hospital costs.

CONCLUSION

This real-world cost analysis demonstrates that the burden of infections and comorbidities, both related to CS use, is higher than that of relapses on hospital costs in AAV patients. Thus, this study implicates clinicians considering hospital costs should focus on reducing CS and achieving CS-free remission to prevent infections and comorbidities.

Для цитирования: van Leeuwen Jolijn R, Soltani Frouzan H, van den Hout Wilbert B, Rabelink Ton J, Teng Y K Onno. Drivers of hospital costs in ANCA-associated vasculitis patients with long-term follow-up-a real-world cost analysis.. Clinical kidney journal. 2025. DOI: 10.1093/ckj/sfaf267.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.